We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Pediatrix Sustain Growth Despite Lower Patient Volumes?
Read MoreHide Full Article
Key Takeaways
Pediatrix's second-quarter revenues grew 4% YoY despite a 2.1% decline in patient volume.
In Q2 2026, same-unit reimbursement revenues rose 4% YoY on better collections, payor mix and acuity.
Pediatrix reaffirmed 2026 adjusted EBITDA guidance of $280-$300 million as volume risks persist.
Pediatrix Medical Group, Inc. (MD - Free Report) delivered steady growth in the second quarter of 2026 despite continued pressure on patient volumes. Net revenues increased 4% year over year to $487.8 million, supported by recent acquisitions and higher same-unit revenues. In the second quarter, same-unit revenues from net reimbursement-related factors rose 4% year over year, offsetting a 2.1% decline in same-unit revenues attributable to patient volume.
Better reimbursement trends remained a key support. Improved RCM cash collections, a favorable payor mix and higher patient acuity, primarily in neonatology, helped lift same-unit pricing. Commercial and other non-government payor mix improved 135 basis points in the second quarter of 2026 from the year-ago period, while adjusted EBITDA increased to $76.4 million from $73.2 million.
Volume trends, however, could remain a constraint. The company expects full-year patient volumes to be roughly flat to slightly lower, consistent with past seasonal patterns. The benefit from stronger revenue-cycle collections is also expected to ease in the second half of 2026. Meanwhile, higher salaries and malpractice expenses could continue to weigh on operating leverage.
MD is expanding telehybrid services across women’s and children’s care and continues to evaluate acquisitions and partnership opportunities. The company also reaffirmed its 2026 adjusted EBITDA outlook of $280-$300 million. Overall, continued acuity gains, favorable payor mix and strategic expansion could support growth, but weaker volumes and easing collection benefits remain key risks.
Tenet Healthcare is benefiting from stronger hospital activity and higher-acuity care. In the second quarter of 2026, hospital unit’s net operating revenues increased 6% year over year, while admissions rose 2.3%. Higher acuity and service intensity are supporting revenue growth, alongside continued expansion of its ambulatory care business.
HCA Healthcare is seeing steady demand across its hospital network. In the second quarter of 2026, admissions increased 2.4%, while revenue per equivalent admission rose 6% year over year. Higher revenue intensity and Medicaid supplemental payments contributed to growth, with emergency-room visits also increasing during the quarter.
MD’s Price Performance, Valuation & Estimates
Shares of MD have gained 56.3% over the past year compared with the industry’s growth of 12.6%.
Image Source: Zacks Investment Research
From a valuation standpoint, Pediatrix trades at a forward price-to-earnings ratio of 11.63, below the industry average of 16.44. MD carries a Value Score of A.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Pediatrix’s 2026 earnings is pegged at $2.32 per share, implying 13.7% growth from the year-ago period.
View the Zacks #1 Rank List
Image: Bigstock
Can Pediatrix Sustain Growth Despite Lower Patient Volumes?
Key Takeaways
Pediatrix Medical Group, Inc. (MD - Free Report) delivered steady growth in the second quarter of 2026 despite continued pressure on patient volumes. Net revenues increased 4% year over year to $487.8 million, supported by recent acquisitions and higher same-unit revenues. In the second quarter, same-unit revenues from net reimbursement-related factors rose 4% year over year, offsetting a 2.1% decline in same-unit revenues attributable to patient volume.
Better reimbursement trends remained a key support. Improved RCM cash collections, a favorable payor mix and higher patient acuity, primarily in neonatology, helped lift same-unit pricing. Commercial and other non-government payor mix improved 135 basis points in the second quarter of 2026 from the year-ago period, while adjusted EBITDA increased to $76.4 million from $73.2 million.
Volume trends, however, could remain a constraint. The company expects full-year patient volumes to be roughly flat to slightly lower, consistent with past seasonal patterns. The benefit from stronger revenue-cycle collections is also expected to ease in the second half of 2026. Meanwhile, higher salaries and malpractice expenses could continue to weigh on operating leverage.
MD is expanding telehybrid services across women’s and children’s care and continues to evaluate acquisitions and partnership opportunities. The company also reaffirmed its 2026 adjusted EBITDA outlook of $280-$300 million. Overall, continued acuity gains, favorable payor mix and strategic expansion could support growth, but weaker volumes and easing collection benefits remain key risks.
How Are Peers Faring?
Some of MD’s peers in the medical space are Tenet Healthcare Corporation (THC - Free Report) and HCA Healthcare, Inc. (HCA - Free Report) .
Tenet Healthcare is benefiting from stronger hospital activity and higher-acuity care. In the second quarter of 2026, hospital unit’s net operating revenues increased 6% year over year, while admissions rose 2.3%. Higher acuity and service intensity are supporting revenue growth, alongside continued expansion of its ambulatory care business.
HCA Healthcare is seeing steady demand across its hospital network. In the second quarter of 2026, admissions increased 2.4%, while revenue per equivalent admission rose 6% year over year. Higher revenue intensity and Medicaid supplemental payments contributed to growth, with emergency-room visits also increasing during the quarter.
MD’s Price Performance, Valuation & Estimates
Shares of MD have gained 56.3% over the past year compared with the industry’s growth of 12.6%.
Image Source: Zacks Investment Research
From a valuation standpoint, Pediatrix trades at a forward price-to-earnings ratio of 11.63, below the industry average of 16.44. MD carries a Value Score of A.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Pediatrix’s 2026 earnings is pegged at $2.32 per share, implying 13.7% growth from the year-ago period.
Image Source: Zacks Investment Research
MD stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.